Justin Bingham has 15 years experience in pharmaceutical research and development and life sciences business development. His experience encompasses novel technologies in stem cell biology, molecular biology, synthetic biology, and bio therapeutic discovery and development. He is a cell biologist by training with a Bachelor of Arts Molecular, Cellular, and Developmental Biology from the University of California at Santa Cruz. He also holds an MBA from the Rady School of Business at the University of California at San Diego. Today, he is the Head of Business Development at SGI-DNA, a Craig Venter company, where he supports strategic relationships with outside partners and out licensing of SGI technology. Prior to SGI, Justin was a founder and the Director of Business Development at MicroStem, Inc. a stem cell technologies company focused on elucidating stem cell and primary cell culture conditions for drug discovery and cell therapy applications. Justin held scientific positions at the Genomics Institute of the Novartis Research Foundation and Pfizer, Inc. where he led preclinical large molecule discovery programs that leveraged outside partnerships.
